GlobeNewswire

Zenas BioPharma Announces New Executive Leadership Appointments

Share

Hua Mu, MD, Ph.D. appointed President, CEO and Acting CMO

Joe Farmer appointed CBO

HONG KONG and BOSTON, May 03, 2021 (GLOBE NEWSWIRE) -- Zenas BioPharma (“Zenas”), a cross-border (China-USA based) biopharmaceutical company committed to the development and delivery of immune-based therapies, today announced the appointment of Hua Mu, MD, Ph.D. as President and Chief Executive Officer and Acting Chief Medical Officer and Joe Farmer as Chief Business and Administrative Officer.

“We are delighted to have Hua join the Zenas executive leadership team,” said Lonnie Moulder, Founder and Executive Chairman. “His extensive experience, including building and leading R&D organizations in China, and his track record of successful development and approval of new drugs in the US and China will be critical as Zenas builds a global organization and advances its innovative pipeline of immune-based therapies.”

Dr. Mu joins Zenas after co-founding Overland Pharmaceuticals and serving as Interim Chief Executive Officer and Chief Medical Officer, while also serving as Venture Partner at Hillhouse Capital. Prior to Overland, Dr. Mu served as Chief Scientific Officer and President of R&D and later Chief Medical Officer of Simcere Pharmaceutical Group and President of Simcere of America Inc. Before Simcere, he was Senior Vice President and Global Head of Product Development Service and Partnership at WuXi AppTec. Prior to WuXi, he was Executive Vice President and Chief Medical Officer at Hutchison MediPharma in China. He previously held clinical development executive roles at several global pharmaceutical companies in the US, including Biogen and Genentech.

Dr. Mu received his Ph.D. from the University of California at Berkeley and completed his post-doctorate training at University of California at San Francisco School of Medicine and University of Washington School of Medicine. He received his MD degree from West China University of Medical Sciences.

“Zenas is an innovative biopharmaceutical company uniquely positioned at the nexus of drug development and product flow between China and the West, with an exceptional management team, a world class investor base, and an impressive pipeline of differentiated programs,” said Dr. Mu. "I am thrilled to work with the entire Zenas team and network of partners to achieve our mission to transform the lives of patients with unmet medical needs by bringing best-in-class immune-based therapies to the world.”

Zenas also announced the appointment of Joe Farmer as Chief Business and Administrative Officer. Mr. Farmer is an accomplished biopharma executive with approximately 25 years of transactional and operational experience working with emerging biotechnology companies at all stages of development, from discovery through commercialization. Prior to joining Zenas, Mr. Farmer served as Chief Operating Officer at Xilio Therapeutics.

Prior to Xilio, Mr. Farmer was the General Counsel and Corporate Secretary at TESARO, where he led the global legal, compliance and government affairs functions and was a key member of the leadership team through its acquisition by GlaxoSmithKline in 2019. He previously served as Chief Corporate Counsel at Cubist Pharmaceuticals through its acquisition by Merck in 2015 and served at other publicly traded companies as General Counsel and Chief Administrative Officer. Mr. Farmer began his career as a corporate attorney at Testa Hurwitz & Thibeault. He received his J.D. from Boston College Law School.

“With the appointments of Hua and Joe, Zenas has further strengthened its executive leadership team,” said Lonnie Moulder. “Their respective expertise in building global organizations and executing corporate development strategy through all phases of drug development and commercialization will be invaluable as we continue to advance our global development programs and expand our novel pipeline.”

About Zenas BioPharma

Zenas BioPharma is a cross-border (China-USA based) biopharmaceutical company committed to becoming a global leader in the development and delivery of immune-based therapies for patients in China and around the world. Zenas is rapidly advancing a deep pipeline of innovative therapeutics that continues to grow through our successful business development strategy. Our experienced leadership team and network of business partners drive operational excellence to deliver potentially transformative therapies to improve the lives of those facing autoimmune and rare diseases. For more information about Zenas BioPharma, please visit www.zenasbio.com and follow us on Twitter at @ZenasBioPharma and LinkedIn.

Contacts

Investor Contact:

Zenas BioPharma
IR@zenasbio.com

Media Contact:

Lauren Bartlett
Zenas BioPharma
lauren.bartlett@zenasbio.com

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire

Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire

New Management Appointments in Golar LNG Ltd.13.5.2021 15:05:36 CEST | Press release

The board of Golar LNG Limited ("Golar") is pleased to announce that they have appointed Mr. Karl Fredrik Staubo as the new Chief Executive Officer of the company in their board meeting on 13th May 2021. Mr. Staubo has since May 2020 been the Chief Executive Officer of Golar LNG Partners LP, recently successfully sold to New Fortress Energy. Since September 2020 Mr. Staubo has also been acting as Chief Financial Officer of Golar. Mr. Staubo has a broad shipping/energy background from Clarksons Platou Securities (2010-2018) and Magni Partners (2018-2020). He has a MA (Business Studies and Economics) from the University of Edinburgh. The board has in the same meeting also appointed Mr. Eduardo Maranhao to take over Mr. Staubo’s role as Chief Financial Officer of Golar. Mr. Maranhao has since 2015 been supporting Golar in different functions including as Chief Financial Officer of Golar Power/Hygo Energy Transition Limited until its recent sale to New Fortress Energy. Prior to joining the

Accumulus Synergy Appoint Francisco Nogueira as Chief Executive Officer13.5.2021 15:00:00 CEST | Press release

Accumulus is the first non-profit corporation designed to establish a relationship between technology, policy and collaboration between drug developers, NGOs, academic institutions and government agencies BURLINGAME, Calif., May 13, 2021 (GLOBE NEWSWIRE) -- Accumulus Synergy, a non-profit corporation intended to support interactions between industry and health authorities worldwide to enable real-time collaboration and data exchange, today announced the appointment of Francisco (Frank) Nogueira as the new chief executive officer (CEO). Mr. Nogueira was previously a vice president of Regulatory Affairs at Roche and served as interim CEO at Accumulus since the fall of 2020. Accumulus Synergy was formed on July 13, 2020, to develop a cloud-based platform to facilitate data and information sharing with the potential to transform the way the biopharmaceutical industry interacts with health authorities. The common-platform approach to data sharing aims to make the regulatory process more eff

Notification on convocation of the Joint Stock Company “Latvijas Gāze” Annual General Meeting of Shareholders13.5.2021 15:00:00 CEST | Press release

The Board of joint stock company “Latvijas Gāze”, registration number: 40003000642, legal address: Aristida Briana iela 6, Riga, LV-1001, Latvia (hereafter – the Company) calls up and announces that Annual General Meeting of Shareholders of the Company will take place on June 15, 2021 at 10.00 at the premises of the Company at Aristida Briana iela 6, Riga, LV-1001, Latvia using electronic means of communication. Agenda: Reports of the Board, the Council and the Audit Committee, and the certified auditor’s opinion.Approval of the Annual Report 2020.Distribution of the profit.Setting of remuneration to the members of the Council and the Audit Committee for the 2020 annual performance.Election of the auditor of the 2020 annual accounts and setting of remuneration to the auditor.Election of the Council and setting of remuneration to the Council. The record date for participation at the Annual General Meeting of Shareholders of the Company is June 7, 2021. Only those persons who are shareho

Vertex Acquires Taxamo to Expand Global Commerce and Compliance Solutions13.5.2021 13:30:00 CEST | Press release

European specialist in tax automation for e-commerce and marketplaces KING OF PRUSSIA, Pa., May 13, 2021 (GLOBE NEWSWIRE) -- Vertex, Inc. (NASDAQ: VERX) (“Vertex” or the “Company”), a leading global provider of tax technology solutions, today announced it has acquired Taxamo, a cloud-based pioneer in tax and payment automation for global e-commerce and marketplaces. Taxamo, headquartered in Ireland, counts many of the leading, high-growth digital service providers among its global customers who rely on its unified platform of integrated capabilities to support indirect tax compliance, with a core focus on online sales, payments, and e-invoicing. “The fabric of today’s global commerce is more connected and complex than ever before,” said Vertex CEO David DeStefano. “Our mission is to enable every business to transact, comply and grow with confidence. We are incredibly excited to bring these new end-to-end solutions to our customers and partners around the world.” Taxamo’s cloud-based so

Results 2021 Annual General Meeting13.5.2021 08:30:00 CEST | Press release

PRESS RELEASE: Amsterdam – 13 May 2021.Intertrust N.V. (“Intertrust”) [Euronext: INTER], a global leader in providing tech-enabled corporate and fund solutions to clients operating and investing in international business, announces that in the Annual General Meeting of 12 May 2021 (2021AGM) the shareholders adopted all voting items on the agenda. At the 2021 AGM a total of 73.59% of the total issued share capital was represented. The results of the votes for each item on the agenda, will be published on our website https://www.intertrustgroup.com/investors/shareholder-information/annual-general-meeting-may-2021/ . Draft minutes of the 2021 AGM will be published no later than three months after the end of the meeting, after which shareholders should have the opportunity to react in the following three months. About Intertrust Intertrust has 4,000+ employees who are dedicated to providing world-leading, specialised administration services to clients in over 30 jurisdictions. This is ampl

Update on Kurdistan Payments13.5.2021 07:51:03 CEST | Press release

Oslo, 13 May 2021 – DNO ASA, the Norwegian oil and gas operator, today reported that Kurdistan’s Minister of Natural Resources has informed the international oil companies operating in the region of an intention to extend the payment period for arrears built up from non-payment of certain invoices in 2019 and 2020. As widely reported, last December the Prime Minister of Kurdistan announced a decision to pay the companies 50 percent of incremental revenue in any month in which Brent prices exceed USD 50 per barrel towards the arrears. The revised terms reduce the payment of the withheld amounts to 20 percent of incremental revenue above USD 50 per barrel. The Minister also advised that all international oil company invoices, including towards withheld amounts, will now be settled within 60 days of receipt. DNO is reviewing its position and will engage with Kurdistan to seek agreement regarding payment terms, interest on the arrears and revised lifting arrangements. – For further informa

Mandalay Resources Corporation Announces Financial Results for the First Quarter of 202113.5.2021 00:05:33 CEST | Press release

TORONTO, May 12, 2021 (GLOBE NEWSWIRE) -- Mandalay Resources Corporation ("Mandalay" or the "Company") (TSX: MND, OTCQB: MNDJF) is pleased to announce its financial results for the quarter March 31, 2021. The Company’s condensed and consolidated interim financial results for the quarter ended March 31, 2021, together with its Management’s Discussion and Analysis (“MD&A”) for the corresponding period, can be accessed under the Company’s profile on www.sedar.com and on the Company’s website at www.mandalayresources.com. All currency references in this press release are in U.S. dollars except as otherwise indicated. First Quarter 2021 Highlights: Quarterly revenue of $52.6 million; highest since Q2 2016;Adjusted EBITDA of $26.1 million; third highest in Company’s history;Adjusted net income of $5.6 million ($0.06 or C$0.08 per share); andConsolidated net income of $25.5 million ($0.28 or C$0.35 per share). Dominic Duffy, President and CEO of Mandalay, commented: “Mandalay Resources is ple